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Teixobactin represents the first member of a newly discovered class of antibiotics that act through inhibition of cell wall synthe-
sis. Teixobactin binds multiple bactoprenol-coupled cell wall precursors, inhibiting both peptidoglycan and teichoic acid syn-
thesis. Here, we show that the impressive bactericidal activity of teixobactin is due to the synergistic inhibition of both targets,
resulting in cell wall damage, delocalization of autolysins, and subsequent cell lysis. We also find that teixobactin does not bind
mature peptidoglycan, further increasing its activity at high cell densities and against vancomycin-intermediate Staphylococcus
aureus (VISA) isolates with thickened peptidoglycan layers. These findings add to the attractiveness of teixobactin as a potential
therapeutic agent for the treatment of infection caused by antibiotic-resistant Gram-positive pathogens.
Antibiotic resistance development is a major threat to humanhealth. Constant development of novel antibiotics is required
to keep pace with the emergence and spread of antibiotic resis-
tance in bacterial pathogens (1). The majority of antibiotics in use
today are derivatives of molecules discovered in the early to mid-
twentieth century. The lack of novel compounds, coupled with the
emergence and spread of antibiotic resistance, has resulted in an
increasingly dangerous situation (2–4).
One approach to discover novel antibiotics is to improve our
ability to cultivate microorganisms that produce them. Tradi-
tional culturing methods allow access to an estimated 1% of the
biodiversity in soil. A novel cultivation technique, using an isola-
tion chip or iChip, provides access to an untapped reservoir of
natural product antibiotics, produced by bacteria that had previ-
ously eluded cultivation efforts. One such organism, Eleftheria
terrae, a previously uncultivated Gram-negative betaproteobacte-
rium, was found to produce a novel depsipeptide antibiotic, called
teixobactin. Teixobactin inhibits cell wall biosynthesis and repre-
sents a new class of antibiotics (5).
The bacterial cell wall contains layers of peptidoglycan, a cross-
linked matrix of linear glycan chains (6). Peptidoglycan cross-
linking is the target of -lactam and glycopeptide antibiotics. In
Gram-positive bacteria, teichoic acid (TA) is also a major compo-
nent of the cell wall. TA includes wall teichoic acid (WTA), con-
nected to peptidoglycan, or lipoteichoic acid (LTA), anchored in
the cytoplasmic membrane. TA plays important roles in bacterial
physiology (7, 8), and teichoic acid biosynthesis is an important
target for antibiotic development (9). Recently, it was shown that
inhibition of teichoic acid biosynthesis can restore susceptibil-
ity to methicillin in methicillin-resistant Staphylococcus aureus
(MRSA) (10).
In a previous study, we found that teixobactin binds lipid II, a
precursor of peptidoglycan biosynthesis, and lipid III, a precursor
of teichoic acid biosynthesis (5). Interestingly, teixobactin was ca-
pable of superior bactericidal and bacteriolytic activity compared
to other cell wall-acting antibiotics, the -lactam oxacillin, or the
glycopeptide vancomycin. Also, resistance to teixobactin was not
detected in a number of in vitro studies. Here, we show that the
ability of teixobactin to simultaneously inhibit peptidoglycan and
teichoic acid biosynthesis triggers synergistic effects, resulting in
increased cell wall damage, delocalization of autolysins, and sub-
sequent lysis and cell death. Furthermore, we demonstrate that
teixobactin does not bind mature peptidoglycan and hence is ca-
pable of effectively targeting vancomycin-intermediate S. aureus
(VISA) strains that have increased cell wall density.
MATERIALS AND METHODS
Antimicrobial agents, bacterial strains, and primers. Teixobactin was
purified according to the procedure described previously (5). Vancomy-
cin and tunicamycin were purchased from Sigma-Aldrich. The bacterial
strains and primers are listed in Table S2 in the supplemental material.
JE2, HG003, and SA113 were used throughout the study. HG003 and
SA113 are closely related laboratory methicillin-susceptible S. aureus
(MSSA) strains. JE2 is a MRSA USA300 isolate. All strains displayed the
same MIC to teixobactin. Strains were selected for specific assays due to
preexisting characterized mutants in those strain backgrounds.
MIC. The MIC was determined by the broth microdilution method
according to CLSI guidelines. Muller-Hinton broth (MHB) was supple-
mented with 0.1% Tween 80 to prevent the absorption of compounds to
plastic surfaces. Cell concentration was adjusted to about 5  105 CFU/
ml, and cells were incubated for 20 h at 37°C. The MIC was defined as the
lowest concentration of antimicrobial agents that resulted in no visible
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growth. The MICs of teixobactin and vancomycin in the presence of pu-
rified cell wall components were measured with the method described
above. Purified peptidoglycan suspension was added to MHB to an optical
density at 600 nm (OD600) of 0.1. The medium containing antibiotics and
peptidoglycan was preincubated at 37°C for 1 h before adding bacterial
cells.
Scanning electron microscopy. Overnight cultures of JE2 in MHB
were diluted 1:100 in 100 ml TSB and incubated at 37°C and 225 rpm to an
OD600 of 0.4 to 0.6. Antibiotics were added at 10MIC, and the cells were
cultivated for an additional 4 h. Cultures were filtered through a cellulose
membrane. The cells on the membrane were fixed with 2.5% glutaralde-
hyde with 0.1 M sodium cacodylate buffer (pH 7.2) for 1 h and treated in
a graded series of 1% OsO4 with 0.1 M sodium cacodylate buffer. Cells
were then dehydrated in ethanol and critical-point dried using CO2. The
samples were sputter-coated with a 5-nm platinum coating and examined
at a 3.0-kV accelerating voltage with a Hitachi S-4800 field emission scan-
ning electron microscope.
Time-dependent killing.An overnight culture of S. aureuswas diluted
in MHB and incubated at 37°C and 225 rpm for 3 h. Antibiotics were
added at 10MIC, and cultures were incubated at 37°C and 225 rpm. At
intervals, 100-l aliquots were removed and centrifuged at 10,000 g for
1 min and resuspended in 100 l of sterile phosphate-buffered saline
(PBS). Tenfold serially diluted suspensions (10l) were plated on Muller-
Hinton agar plates. The plates were incubated at 37°C overnight.
Bacteriolytic assay. The bacteriolytic activity in supernatant of cell
cultures was determined by the change of turbidity of the substrate, heat-
killed RN4220 cells (11). The cells were incubated at 37°C until reaching
mid-exponential phase (OD600 of 0.4 to 0.6). Antibiotics were added at
10 MIC, and cultures were incubated at 37°C and 225 rpm for 4 h.
Filter-sterilized culture supernatant was mixed with heat-killed cells ad-
justed to an OD600 of 0.5 and incubated at 37°C for 6 h. The turbidity was
measured every 30 min. The remaining quantity was expressed as the ratio
to initial values.
Zymographic analysis. Murein hydrolase profiles were analyzed by
zymogram (12, 13). Antimicrobial agents at 10 MIC were added to
mid-exponential-phase JE2 cells in 15 ml Trypticase soy broth (TSB), and
the cells were cultivated for an additional 4 h. Cultures were centrifuged
and supernatants and cells were collected separately. The supernatants
were concentrated using an Ultra-4 3000 molecular-weight-cutoff filter
(Amicon) to 500 l. The concentration of protein was determined by the
Bio-Rad protein assay method by following the manufacturer’s instruc-
tions. The cells were washed with 0.1 M Tris-HCl (pH 6.8) once and
treated with sample buffer (2% SDS with -mercaptoethanol) and incu-
bated at 65°C for 5 min. After centrifugation, the supernatants were stored
at 80°C until analysis could be performed. The samples were electro-
phoresed in an 8% SDS-PAGE gel containing heat-killed RN4220 cells as
a substrate (final OD600, 10). After electrophoresis, the gel was washed
with Tris-buffered saline (TBS; 50 mM Tris, 150 mM NaCl, and 3 mM
KCl, pH 7.5) buffer containing 1% Hanks buffer (Sigma) and 2.5% Tri-
ton-X and incubated in TBS buffer containing 1% Hanks buffer and 10
mM CaCl2 at 37°C overnight. The clear zone, which indicated a protein
with autolysis activity, appeared as a dark band in Fig. 2B (see also Fig. S1A
in the supplemental material).
Quantitative real-time PCR. RNA purification was performed as pre-
viously reported (14). Antimicrobial agents at 10 MIC were added to
mid-exponential-phase USA300 cells, and the cells were incubated for 1 h.
The cells were collected and treated with RNAprotect bacterial reagent
(Qiagen) to ensure RNA integrity. Cells were pelleted, suspended in 50
mM EDTA with 0.6 mg/ml lysostaphin (Sigma), and incubated at 37°C for
2 min to lyse the cell. Total RNA was isolated using an RNeasy minikit
(Qiagen) according to the manufacturer’s instructions. To remove DNA,
a Turbo DNA-free kit (Ambion) was used. The integrity of purified RNA
was confirmed by an RNA 600 Nano kit and bioanalyzer (Agilent). RNA
was reverse transcribed into cDNA using high-capacity cDNA reverse
transcription kits (Applied Bioscience). Quantitative real-time PCR was
conducted with using Power SYBR green master mix (Thermo Fisher)
and the ABI Prism 7000 sequence detection system (Applied Bioscience).
The 16S gene was used as the internal standard.
Western blotting. For Western blotting, the samples were run in SDS-
PAGE gel (NuPAGE with 4 to 12% Bis-Tris gel; Novex). The proteins were
transferred onto an Immobilon-P polyvinylidene difluoride (PVDF)
membrane (0.45-m pore size; Millipore) with the XCell II blot module
(Invitrogen). Once transferred, immunoblotting was carried out using a
WesternBreeze chemiluminescent Western blot immunodetection kit ac-
cording to the manufacturer’s instructions (Invitrogen). The membrane
was washed, blocked with nonspecific antibody, and treated with anti-Atl
antibody (12) for 1 h. Finally, the membrane was washed and incubated
with anti-rabbit IgG secondary antibody. After incubation of the mem-
brane with substrate, the blot was analyzed by a gel imaging system (Bio-
Rad).
Isolation of peptidoglycan. Isolation of peptidoglycan for competi-
tion assay was described previously (15). Exponential-phase HG003 cells
were harvested by centrifugation, washed with ice-cold saline, and resus-
pended in 2 ml of saline. The cells were boiled for 20 min. After centrifu-
gation, the cells were resuspended with saline, mixed with glass beads, and
lysed by bead beater (2 rounds, with 20 s at the highest speed and cooling
on ice for 5 min). After harvesting the suspensions, the cells were collected
by centrifugation, suspended in 1 ml 2% SDS, and boiled for 30 min. After
cooling to room temperature, the cells were washed with distilled water at
least 5 times. The pellets were dissolved in 0.1 M Tris-HCl (pH 6.8) with
trypsin (0.5 mg/ml; Sigma) and incubated at 37°C overnight. Finally, the
pellets were washed with distilled water 3 times. This suspension was
stored at80°C until used for competition assay.
Isolation and detection of cell wall teichoic acid. Isolation of teichoic
acid was conducted as follows (16). Antimicrobial agents (teixobactin and
vancomycin [10 MIC] as well as tunicamycin [0.025 MIC]) were
added to mid-exponential-phase HG003 cells in MHB, and the cells were
cultivated for an additional 4 h. Cell pellets were collected by centrifuge,
washed with 50 mM 2-(N-morpholino)ethanesulfonic acid (MES; pH
6.5), resuspended in 0.5 ml 50 mM MES (pH 6.5) with 4% (wt/vol) SDS,
and boiled for 1 h. The cells then were collected by centrifugation and
washed with 50 mM MES (pH 6.5) with 4% SDS twice, washed with 50
mM MES (pH 6.5) with 2% (wt/vol) NaCl, and finally washed with 50
mM MES (pH 6.5). The cells were resuspended with 20 mM Tris-HCl (pH
8.0) with trypsin (0.5 mg/ml) and incubated at 37°C overnight. Following
this, the pellets were washed with distilled water at least 3 times. Pellets
were then suspended with 0.1 ml of 0.1 M NaOH and incubated at room
temperature overnight. Supernatants were used for competition assay or
detection of WTA by SDS-PAGE. Samples were run in SDS-PAGE gel
(16% Tris-Tricine gel; Novex), and the gel was stained by a Pierce silver
stain kit (Thermo Fisher) by following the manufacturer’s procedure.
PurificationofAtlR1–3 andconjugationwithCy3dye.The three-Atl-
repeat domain, R1–3 (17, 18), was expressed with a N-terminal His6 tag in
Escherichia coli M15 using the isopropyl--D-thiogalactopyranoside
(IPTG)-inducible plasmid pEQ30Atl R1–3 (19, 20). Cells were cultivated
in 2 yeast extract-tryptone broth (YT) to an OD of 0.5 at 37°C and then
induced with 0.5 mM IPTG for 4 h at 20°C. The cells were harvested by
centrifugation and washed twice in PBS containing complete protease
inhibitor cocktail (Roche); the cell pellet was lysed using a French press.
The crude extract was centrifuged (5,000 g), and R1–3–His was affinity
purified with nickel-nitrilotriacetic acid (Ni-NTA) superflow (Qiagen) as
described by the manufacturer. The imidazole elution buffer was then
exchanged by PBS using a Vivaspin 2 column with a 10-kDa cutoff (Sar-
torius). For protein conjugation with Cy3, the Amersham Cy3 antibody
labeling kit (GE) was used. Conjugation of His6R1–3 and the separation of
protein from free dye were performed as described by the manufacturer.
Epifluorescence microscopy. Localization of Atl on the cell surface
exposed to antibiotics was determined similarly to a previous study (21).
Antimicrobial agents at 10MIC were added to mid-exponential-phase
HG003 cells in MHB, and the cells were cultivated for an additional 30
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min. The cells were washed twice with PBS and incubated with Cy3-R1–3
for 5 min at room temperature. After washing twice with PBS, a 2-l cell
suspension was applied to glass slides and distribution of fluorescence was
confirmed with a Leica fluorescence microscopy system.
RESULTS
Teixobactin-induced lysis is dependent on the Atl autolysin.
Teixobactin has been shown to have excellent bactericidal activity
against S. aureus (5). We examined the effect on cell morphology
of teixobactin and vancomycin after 4 h of exposure at 10MIC
by electron microscopy (Fig. 1A). Exposure to teixobactin results
in collapse of the cell wall, while vancomycin damage to the cell
wall was less severe.
-Lactam-induced lysis is known to be mediated by Atl, the
major cell wall autolysin of S. aureus (17, 22). To investigate the
contribution of Atl to the activity of teixobactin, the antibac-
terial activity against an atl mutant from the Nebraska trans-
poson insertion library (available through BEI [https://www
.beiresources.org/]) was examined and compared to wild-type
strain JE2. Although the MIC of teixobactin was not affected by
mutation of atl (see Table S1 in the supplemental material), the
bactericidal activity was markedly reduced. Teixobactin did not
significantly reduce the viable cell count of the atl mutant after
24 h of exposure, compared to a 3-log reduction in CFU per mil-
liliter in the wild-type strain (Fig. 1B). Also, 24 h of teixobactin
exposure did not cause lysis in an atl mutant, confirming the lysis
phenotype is Atl dependent (Fig. 1C).
Teixobactin causes adecrease inatl expression.Teixobactin’s
bactericidal activity is dependent on Atl; hence, we decided to
examine the lytic capacity of the supernatant of a culture treated
with teixobactin. Atl undergoes maturation by proteolytic pro-
cessing, resulting in generation of two extracellular lytic enzymes,
an amidase and a glucosaminidase (12, 14, 23). If teixobactin
treatment resulted in increased lytic enzyme production, we
would expect the supernatant to have increased lysis capacity. To
test this, we performed bacteriolytic assays with supernatants of
treated and untreated cultures (Fig. 2A). The untreated control
supernatant had marked lytic activity and strongly reduced the
turbidity of a cell suspension over time. On the other hand, the
supernatant of a teixobactin-treated culture did not have any vis-
ible lytic capacity. To further investigate this, we examined the
lysis profile of the extracellular and cell wall-anchored Atl with
zymography (Fig. 2B). Both supernatant and cell wall-associated
protein isolated from cells treated with 10 MIC of teixobactin
for 4 h showed reduced murein hydrolase activity compared to
those from untreated samples (see Fig. S1A in the supplemental
material). Furthermore, real-time PCR revealed that expression of
FIG 1 Antibacterial activity of teixobactin is dependent on autolysin. (A) Scanning electron microscopy of S. aureus JE2 revealed cell wall damage in response
to teixobactin (10 MIC). The scale bars for upper and lower pictures indicate 0.1 m and 1 m, respectively. AB, antibody; Teix, teixobactin; Vanc,
vancomycin. (B) Time-dependent killing by teixobactin (10MIC) against JE2 and its isogenicatlmutant. (C) The turbidity of JE2 and theatlmutant before
and after exposure of teixobactin (10MIC) for 24 h (right). The OD600 was measured. These data represent the means and standard deviations (SD) from 3
independent experiments.
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atl in teixobactin-treated cells was about 25-fold lower than that in
untreated control cells (Fig. 2C). Finally, the reduced Atl levels
were confirmed by Western blot analysis (see Fig. S1B). Vanco-
mycin also reduced the murein hydrolase activity (Fig. 2A to C),
which has been reported previously (24, 25). These results suggest
that lipid II inhibition results in the activation of a signal trans-
duction pathway that results in reduced autolysin expression, pre-
sumably to reduce cell death in the presence of this extreme cell
wall stress. Importantly, the reduction of autolysins in the super-
natant in response to antibiotic occurs after 2 to 4 h of exposure
(see Fig. S1A).
Teixobactin causes Atl-dependent cell lysis but paradoxically
causes inhibition of autolysin expression. Hence, the teixobactin-
treated cell wall must be more susceptible to autolysins present at
the time of addition of the antibiotic.
Teixobactin-induced lysis is enabled by inhibition of cell
wall teichoic acid biosynthesis. The localization of Atl at the sep-
tum to mediate cell division has been proposed to occur via exclu-
sion from the rest of the cell wall by the presence of teichoic acids
(21). In the absence of WTA, Atl binding on the cell surface is
delocalized, causing lysis (21). Furthermore, WTA are required
for -lactam resistance in methicillin-resistant S. aureus, and the
cells which lack WTA are sensitized to -lactam-induced cell lysis
(26–28). The genes involved in teichoic acid biosynthesis are
called the tar genes (for teichoic acid ribitol). TarO (previously
referred to as TagO), an N-acetylglucosamine-1-phosphate trans-
ferase, catalyzes the first step in this biosynthetic pathway, and
mutation of tarO results in a teichoic acid-deficient strain (29).
We examined cell lysis of wild-type and tarO mutant strains in the
presence of vancomycin and teixobactin. As previously reported,
teixobactin causes increased lysis of the wild-type strain compared
to vancomycin. Both antibiotics caused lysis of the tarO mutant,
demonstrating that lipid II inhibition results in cell lysis, but only
in a teichoic acid null background (Fig. 3A and B). As teixobactin
blocks lipid II and lipid III, this suggests that the lytic activity of
teixobactin is due to the combined inhibition of both targets. To
FIG 2 Teixobactin causes downregulation of atl expression. (A) Bacteriolytic
assay using supernatant from JE2 incubated with teixobactin (10 MIC) or
vancomycin (10MIC) for 4 h. (B) Zymography of teixobactin-treated sam-
ples on SDS-PAGE gel containing heat-killed S. aureus RN4220 as a substrate.
The dark bands indicate the clear zone in the SDS-PAGE gel, which is caused
by the lysis of substrate. Left and right lanes were supernatant (Sup) and cell
wall-associated samples (CW), respectively. (C) Comparison of atl transcrip-
tion by quantitative real-time PCR. The bars indicate the relative values com-
pared to the no-antibiotic-treatment sample. These data represents the means
and SD from 3 independent experiments.
FIG 3 Inhibition of WTA biosynthesis is responsible for teixobactin-mediated lysis. The lysis of SA113 (A) and the SA113 tarO mutant (B) was induced by
teixobactin (10MIC) or vancomycin (10MIC). The OD600 was measured every 30 min for 16 h. Time-dependent killing (C) and the change of turbidity (D)
of HG003 by combination of tunicamycin (Tuni; 0. 4 g/ml; 0.025 MIC) and teixobactin (10 MIC) or vancomycin (10 MIC). These data represent the
means and SD from 3 independent experiments. (E) The detection of WTA purified from HG003 exposed to antibiotics in SDS-PAGE gel. The concentrations
of teixobactin and tunicamycin were 5 g/ml (10MIC) and 0.4 g/ml (0.025MIC), respectively. The gel was stained by a silver stain kit.
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further examine a potential synergistic relationship between inhi-
bition of peptidoglycan and teichoic acid biosynthesis, we exam-
ined the bactericidal and lytic activity of vancomycin with tunica-
mycin, a known inhibitor of WTA synthesis against cultures of the
S. aureus laboratory strain HG003 (27) (Fig. 3C and D). We found
that indeed, the combination of tunicamycin and vancomycin re-
sults in increased killing relative to vancomycin alone, and cell
lysis was increased (Fig. 3C and D). We next examined the effect of
teixobactin on teichoic acid levels. Teichoic acids were isolated
from the cell wall before and after 4 h of teixobactin treatment.
Results clearly showed that teixobactin treatment results in mark-
edly reduced quantities of teichoic acid in the cell wall (Fig. 3E).
In an attempt to identify the signal transduction pathway lead-
ing to atl downregulation, we examined the MIC activity of teixo-
bactin, oxacillin, and vancomycin against 12 mutants of two-com-
ponent regulatory systems (see Table S3 in the supplemental
material). These mutants were from the JE2 ordered mutant li-
brary. The saeS mutation resulted in a dramatic 16-fold reduc-
tion in MIC to teixobactin but only a modest 2-fold decreased
MIC to vancomycin. We then performed killing experiments and
found that vancomycin displayed bactericidal killing against a
saeS mutant but not the JE2 parental strain (Fig. 4A). Surpris-
ingly, preliminary analysis showed an apparent decreased abun-
dance of WTA in the saeS mutant (Fig. 4B). SaeRS is known to
regulate virulence determinants, including surface proteins, tox-
ins, and capsule biosynthesis components (30–32), and the saeR
mutant shows high susceptibility to -lactams in Staphylococcus
epidermidis (33). This increased susceptibility to cell wall-acting
antibiotics may be due to decreased teichoic acids in the cell wall.
This would further corroborate the role of teichoic acids in pre-
vention of lysis mediated by lipid II inhibition. Again, teixobac-
tin’s ability to inhibit both peptidoglycan and teichoic acid bio-
synthesis explains its ability to kill and lyse S. aureus so efficiently.
More work is required to more precisely measure the impact of
saeS mutation on teichoic acid content of the cell wall and eluci-
date how the SaeRS two-component system could influence WTA
levels in S. aureus.
Teixobactin treatment results in delocalization of autoly-
sins. It has been proposed that teichoic acids control autolysin
binding to peptidoglycan by an exclusion principle, whereby cell
wall teichoic acid interaction with peptidoglycan inhibits autoly-
sin binding (21, 34). Consequently, an absence of teichoic acids at
the septum facilitates appropriate localization of autolysins dur-
ing cell division. It was also shown that mutation of tarO results in
delocalization of amidase (21). Atl possesses three repeat se-
quences, each about 150 amino acids long (R1–3), which bind to
peptidoglycan (19, 35). We examined the localization of Atl using
a fluorescently labeled R1–3 repeat domain (Cy3-R1–3) (21). We
found that Cy3-R1–3 delocalization occurs in cells treated with
teixobactin for 30 min, similar to that previously seen in a tarO
mutant. These experiments were performed against the model
laboratory strain HG003 (Fig. 5; see also Fig. S2 in the supplemen-
tal material). This suggested that teixobactin treatment resulted in
delocalization of Atl due to inhibition of WTA biosynthesis of the
cell. This delocalization explains the intense lytic capacity of teixo-
bactin. Vancomycin did not cause delocalization of the amidase
over a similar time period. A longer 4-h treatment with vancomy-
cin did result in delocalization of the fluorescent amidase. Delo-
calization by teixobactin is rapid and does not allow the cell time
to reduce autolysin production and limit Atl-mediated damage.
Collectively, these results suggest that coinhibition of lipid II and
lipid III by teixobactin causes a pronounced weakening of the cell
wall compared to lipid II inhibition alone. This results in increased
delocalization of autolysins, leading to cell lysis and death.
Teixobactin does not bind cell wall peptidoglycan. We have
previously shown that teixobactin has killing activity superior to
that of vancomycin against dense populations of S. aureus (5).
This is due in part to teixobactin’s ability to inhibit teichoic acid
production. However, a further important limitation of vancomy-
cin activity, particularly at high cell densities, is the binding of
vancomycin to mature peptidoglycan. Vancomycin has no anti-
bacterial activity when bound to mature peptidoglycan. This ex-
plains the reduced bactericidal activity of vancomycin against
dense populations of cells. Furthermore, this circumstance can
lead to vancomycin-intermediate resistance. Many VISA strains
have thicker cell walls with altered cross-linking (36). This leads to
increased binding of vancomycin to mature peptidoglycan at the
D-Ala-D-Ala pentapeptide and sequestration of the antibiotic.
Teixobactin does not bind the pentapeptide; hence, it may not
FIG 4 Mutation of saeS results in sensitization to vancomycin due to de-
creased WTA. (A) Time-dependent killing of JE2 saeS mutant by vancomy-
cin (10 MIC). These data represent the means and SD from 3 independent
experiments. (B) The detection of WTA purified from JE2 saeS mutant in
stationary phase. The gel was stained by a silver stain kit.
FIG 5 Teixobactin treatment causes Atl delocalization. In vitro binding of
amidase repeats (Cy3-R1–3) with the cell treated with teixobactin. S. aureus
HG003 exposed to teixobactin (10 MIC) or vancomycin (10 MIC) was
incubated with Cy3-R1–3 and visualized with fluorescence microscopy. The
phase contrast and fluorescent images (red color) were merged. The scale bar
represents 1 m.
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bind the mature cell wall peptidoglycan. To test this, we purified
peptidoglycan from S. aureus HG003 and performed MIC testing
after a preincubation of vancomycin or teixobactin with purified
peptidoglycan (Table 1). Interestingly, the MIC to vancomycin
increased 16-fold after this preincubation due to binding with
peptidoglycan decreasing the concentration of active antibiotic in
the medium. Incubation with teixobactin, on the other hand, re-
sulted in only a modest 2-fold increase in MIC, and this did not
increase with higher concentrations of peptidoglycan (note that
the intrinsic variability in MIC determination is also 2-fold). This
showed that teixobactin does not bind mature peptidoglycan,
which likely contributes to its activity against dense populations of
S. aureus and its activity against all VISA strains examined.
DISCUSSION
Teixobactin represents a recently discovered class of antibiotics,
and it exhibits a number of unique and desirable characteristics.
These include an apparent absence of resistance development and
an improved lytic capacity compared to the cell wall-acting anti-
biotics oxacillin and vancomycin. In this study, we sought to fur-
ther explore the mechanism of action of teixobactin and how it
yields the intense lytic and bactericidal activity against S. aureus,
including VISA isolates. We find that teixobactin exhibits excel-
lent bacterial killing, likely due to the synergistic inhibition of both
peptidoglycan and WTA biosynthesis. In spite of downregulation
of Atl, inhibition of teichoic acid biosynthesis and peptidoglycan
results in significant Atl-mediated lysis and cell death. We also
find that teixobactin does not bind to and hence is not antago-
nized by mature peptidoglycan, explaining activity against VISA
isolates. We find that sub-MIC levels of tunicamycin enhanced the
bactericidal activity of vancomycin without affecting the MIC. At
this concentration (0.4 g/ml), tunicamycin inhibits the biosyn-
thesis of WTA without affecting cell growth. This showed that lack
of WTA enhanced the killing by lipid II inhibition. Bactericidal
activity of teixobactin plus tunicamycin was stronger than that of
vancomycin plus tunicamycin. This may be due to the different
stages of teichoic acid biosynthesis that are inhibited by tunicamy-
cin and teixobactin. In the WTA biosynthesis pathway, the first
two enzymes, TarO and TarA, are not essential under laboratory
conditions, while most of the downstream factors are essential
(37). The mechanism of this lethality may be due to accumulation
of toxic intermediates or to depletion of cellular pools of cell wall
precursors (37). Teixobactin is thought to inhibit the later steps of
WTA biosynthesis by binding to lipid III outside the cell mem-
brane (5). Interestingly, the teichoic acid profile from cells treated
with tunicamycin or teixobactin is markedly different, presum-
ably due to the different stages of biosynthesis inhibited by each
compound.
Teixobactin causes the downregulation of atl gene expression.
It has already been reported that inhibition of peptidoglycan bio-
synthesis elicits various secondary responses and downregulation
of atl expression (24, 38). In prokaryotes, sensing and signal trans-
duction is primarily conducted by two-component systems
(TCSs), consisting of a histidine kinase sensor and a cognate re-
sponse regulator. There are 16 pairs of TCSs in S. aureus, and some
of them are involved in autolysis control, biofilm formation, cell
wall synthesis, or drug resistance (39). Among these systems,
WalKR is essential for viability and is involved in cell wall metab-
olism. A strain expressing a constitutively active form of WalR
displays upregulated atl transcription (40). GraRS is a well-stud-
ied system which regulates the resistance to cationic antimicrobial
peptides. A graRS mutant displays reduced expression of atl
(41). These findings suggest that atl transcription is inactivated via
WalKR and/or GraRS systems under cell wall stress conditions.
Here, we find that mutation of saeS of the SaeRS two-component
system resulted in increased sensitivity to killing by vancomycin
independent of an effect on atl expression. Mutation of saeS re-
sults in loss of teichoic acid in the cell wall, resulting in sensitivity
to lysis by lipid II inhibition. With this in mind, inhibitors of
two-component systems, particularly WalKR, GraRS, and SaeRS,
have the potential to further sensitize cells to cell wall-acting an-
tibiotics and may result in improved bactericidal activity.
Intriguingly, teixobactin exhibits potent activity against M. tu-
berculosis (5). Mycobacterium has a unique cell wall structure
composed of arabinogalactan, peptidoglycan, and mycolic acid
(42). The mechanism of ethambutol, an antituberculosis agents, is
inhibition of arabinogalactan biosynthesis (43). Recently, it was
reported that the inhibitor of WecA, which is the ortholog of TarO
and is involved in arabinogalactan biosynthesis, has good antitu-
bercular activity (44). It will be interesting to examine teixobac-
tin’s proposed ability to inhibit arabinogalactan and how the dual
inhibition of peptidoglycan and arabinogalactan synthesis may
result in enhanced bactericidal activity against this important hu-
man pathogen.
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